MELBOURNE, Australia and INDIANAPOLIS, Feb. 20, 2026 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces its financial results for the year ended December 31, 2025. FY 2025 key results1 Group performance2: Double-digit revenue growth and positive adjusted operating cash flow Revenue of US$803.8 million, up by 56%3 and achieving upsized full year […]
Category Archives: Pr Newswire
In the news release, ” Republic Power Group Limited Announces 1-For-20 Reverse Share Split”, issued on February 20, 2026 by Republic Power Group Limited over PR Newswire, we are advised by the company that the market effective date of the reverse share split should be February 24, 2026, rather than February 23, 2026, as originally […]
STOCKHOLM, Feb. 20, 2026 /PRNewswire/ — Building on the merger of Permascand and Magneto Special Anodes, the company now enters a new chapter as Elicron. The new name reflects a strong legacy and an ambition to support customers’ operational excellence in evolving markets. A year ago, Permascand merged with Magneto Special Anodes, establishing a leading […]
NEW YORK, Feb. 20, 2026 /PRNewswire/ — White Pearl Acquisition Corp. (NYSE: WPAC U) (the “Company”) today announced that, commencing February 24, 2026, holders of the units sold in the Company’s initial public offering may elect to separately trade the Company’s Class A ordinary shares and rights included in the units. No fractional rights will be […]
The World Health Organization (WHO)–World Meteorological Organization (WMO) Climate and Health Joint Programme, The Rockefeller Foundation, and Wellcome announce new regional efforts to connect climate science to health action to prevent heat impacts, help communities flourish, and save lives. MUMBAI, India, Feb. 20, 2026 /PRNewswire/ — At Mumbai Climate Week, the WHO-WMO Climate and Health Joint […]
Pr Newswire
Step Pharma secures €2.5 million EIC grant to accelerate development of dencatistat for CTPS2 null gynaecological tumours
19
Feb
Feb
Blended finance award also includes up to €10 million in equity investment from the EIC Step Pharma’s lead product, dencatistat, expected to begin evaluation in phase 1b expansion cohorts for CTPS2 null ovarian and endometrial cancers later in 2026 Saint-Genis-Pouilly, France, 19 February 2026 – Step Pharma (“the Company”), the global leader in CTPS1 inhibition […]
Pr Newswire
InterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Million, Positive Adjusted EBITDA and Cash of NIS 43 Million
19
Feb
Feb
InterCure reports preliminary estimated revenue of NIS 265 million for 2025 and positive Adjusted EBITDA, marking its twelfth consecutive half-year of positive Adjusted EBITDA. Revenue for 2025 represents an increase of approximately 11% compared to 2024, while revenue for the second half of 2025 is nearly 20% higher than the corresponding period in the prior […]
Pr Newswire
Leading Scientists Demonstrate How Seer’s Proteograph Product Suite Advances Cardiovascular and Neurodegenerative Research at US HUPO 2026
19
Feb
Feb
Nathan Basisty, Sasha Singh, Bruce Wilcox, and Mozhgan Boroumand among scientific leaders presenting unique proteomics-enabled biological insights REDWOOD CITY, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) — Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced its participation in the 2026 U.S. Human Proteome Organization (US HUPO) Annual Conference, […]
Pr Newswire
NovaBridge Appoints Biotech Leader, Emmett T. Cunningham, Jr, MD, PhD, MPH, as Vice Chairman of the Board to Further Accelerate Global Biotech Platform
19
Feb
Feb
Appointment is a positive endorsement of NovaBridge’s unique hub-and-spoke model and focus on creating shareholder value by accelerating the development of transformative medicines for patients around the world As a physician-entrepreneur and founder with a proven track record in business development, Dr. Cunningham aims to bolster NovaBridge’s mission to accelerate access to transformative medicines Dr. […]
Pr Newswire
Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)
19
Feb
Feb
FOP is an ultra-rare genetic disorder characterized by abnormal bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability If approved, garetosmab would be the first and only available treatment shown to reduce the number and volume of new heterotopic bone lesions in adults with FOP TARRYTOWN, N.Y., Feb. 19, […]